Determining serum cold agglutinins is a complementary test for diagnosing atypical Mycoplasma pneumonia and investigating certain hemolytic anemias.
More information
Agglutinins are antibodies that cause red blood cells to clump or stick together. These antibodies can cause hemolytic anemia. It is essential to know which type of agglutinin is causing hemolytic anemia so that appropriate treatment can be initiated. Cold agglutinins are active at low temperatures. These antibodies, mainly IgM class, are most active at temperatures below 37° C, hence the term "cold-."
The test is used to diagnose hemolytic anemia due to the presence of cold agglutinins (cold agglutinin disease) and often for the indirect diagnosis of atypical pneumonia caused by Mycoplasma pneumoniae. Cold agglutinins usually increase 8 to 10 days after the onset of atypical pneumonia, peak 12 to 25 days later, and begin to decline 30 days after onset.
Antibiotics may affect the production of cold agglutinins.
Possible Interpretations of Pathological Values
- Increase: Hemolytic anemia, Hodgkin's disease, infectious mononucleosis, lymphoma, malaria, multiple myeloma, atypical pneumonia due to Mycoplasma pneumoniae, scleroderma, syphilitic cirrhosis, viral pneumonia
Important Note
Laboratory test results are the most critical parameter for diagnosing and monitoring all pathological conditions. Between 70 to 80% of diagnostic decisions are based on laboratory tests. Correctly interpreting laboratory results allows a doctor to distinguish "healthy" from "diseased."
Laboratory test results should not be interpreted from the numerical result of a single analysis. Test results should be analyzed based on each case and family history, clinical findings, and the results of other laboratory tests and information. Your physician should explain the importance of your test results.
At Diagnostiki Athinon, we answer any questions you may have about the test you perform in our laboratory and contact your doctor to ensure you receive the best possible medical care.
